Find latest Myeloma videos
·
100+ videos
Optimizing the Management of Multiple Myeloma in the Early R/R Setting
In a recent interactive webinar, renowned experts Prof. Aurore Perrot, Prof. Hermann Einsele, Assoc. Prof. Karthik Ramasamy and Assoc. Prof. Joshua Richter discuss the challenges of optimising treatment for early relapsed/refractory multiple myeloma (RRMM), exploring current treatment options and sharing insights from clinical practice.
Watch this on-demand video to hear the medical experts discuss:
- Current treatments for early RRMM: Linking mechanism of action to efficacy
- Best practices in combining and sequencing therapies for optimal outcomes in early RRMM
- Insights from clinical practice on how to manage tolerability and safety
Clinical takeaways
Myeloma is a continually evolving field with modern day induction regimens yielding near 100% response rates in the front-line setting with typically durable remissions
This has been achieved through triplets and quadruplets comprised of the 3 classic MOAs: IMiD, PI, mAb
In the relapsed/refractory space it is important to embrace novel MOAs/targets to optimally manage recurrent disease: XPO1, BCMA, GPRC5d
T-cell health is an important long-term consideration for patients to maximise efficacy of T-cell redirection therapy
Treatments that are T-cell-sparing, such as XPO1 inhibitors and IMiDs, have the potential to preserve T-cell health
The event concluded with speakers and participants engaging in patient case study discussion and Q&A to address pressing questions.
Watch the video replay and download the accompanying slides by visiting the COR2ED website.
June 2024
Watch this on-demand video to hear the medical experts discuss:
- Current treatments for early RRMM: Linking mechanism of action to efficacy
- Best practices in combining and sequencing therapies for optimal outcomes in early RRMM
- Insights from clinical practice on how to manage tolerability and safety
Clinical takeaways
Myeloma is a continually evolving field with modern day induction regimens yielding near 100% response rates in the front-line setting with typically durable remissions
This has been achieved through triplets and quadruplets comprised of the 3 classic MOAs: IMiD, PI, mAb
In the relapsed/refractory space it is important to embrace novel MOAs/targets to optimally manage recurrent disease: XPO1, BCMA, GPRC5d
T-cell health is an important long-term consideration for patients to maximise efficacy of T-cell redirection therapy
Treatments that are T-cell-sparing, such as XPO1 inhibitors and IMiDs, have the potential to preserve T-cell health
The event concluded with speakers and participants engaging in patient case study discussion and Q&A to address pressing questions.
Watch the video replay and download the accompanying slides by visiting the COR2ED website.
June 2024
Comments 0
Login to view comments.
Click here to Login
